Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche.

International Journal of Molecular Sciences
Christine VignonOlivier Herault

Abstract

The bone marrow (BM) microenvironment plays a crucial role in the development and progression of leukemia (AML). Intracellular reactive oxygen species (ROS) are involved in the regulation of the biology of leukemia-initiating cells, where the antioxidant enzyme GPx-3 could be involved as a determinant of cellular self-renewal. Little is known however about the role of the microenvironment in the control of the oxidative metabolism of AML cells. In the present study, a coculture model of BM mesenchymal stromal cells (MSCs) and AML cells (KG1a cell-line and primary BM blasts) was used to explore this metabolic pathway. MSC-contact, rather than culture with MSC-conditioned medium, decreases ROS levels and inhibits the Nrf-2 pathway through overexpression of GPx3 in AML cells. The decrease of ROS levels also inactivates p38MAPK and reduces the proliferation of AML cells. Conversely, contact with AML cells modifies MSCs in that they display an increased oxidative stress and Nrf-2 activation, together with a concomitant lowered expression of GPx-3. Altogether, these experiments suggest that a reciprocal control of oxidative metabolism is initiated by direct cell-cell contact between MSCs and AML cells. GPx-3 expression appears to pla...Continue Reading

References

Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·K G MendelsonK E Paulson
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 31, 2002·Blood·Jalila ChagraouiPierre Charbord
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna van RhenenGerrit Jan Schuurhuis
Oct 24, 2007·Nature Biotechnology·Fumihiko IshikawaLeonard D Shultz
Feb 26, 2010·Nature Reviews. Immunology·Andreas TrumppAnne Wilson
Dec 3, 2010·Nature·Sushma GurumurthyNabeel Bardeesy
Mar 15, 2011·Blood·Paul Spencer HoleAlex Tonks
Apr 18, 2012·The Journal of Experimental Medicine·Olivier HeraultGuy Sauvageau
May 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Eri Taniguchi IshikawaJose A Cancelas
Feb 26, 2013·Nature Cell Biology·Jennifer J TsaiMarcel R M van den Brink
Oct 11, 2013·Nature·Yuya KunisakiPaul S Frenette
Dec 3, 2014·Biochemical and Biophysical Research Communications·Ayako Nakamura-IshizuToshio Suda
Jul 30, 2015·Nature Communications·Maria MaryanovichAtan Gross
Nov 11, 2015·The Journal of Experimental Medicine·Ayako Nakamura-IshizuToshio Suda
Jul 19, 2016·Nature Cell Biology·Navdeep S ChandelEmmanuelle Passegué
Oct 13, 2016·Nature Communications·Nicola VanniniMatthias P Lutolf

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
dissect
nuclear translocation
density gradient centrifugation
fluorescence-activated cell sorting
FACS
Protein Extraction
protein assay

Software Mentioned

Diva
FlowJo
ProbeFinder
R

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.